TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with painful osteoarthritis of the knee.~* The pain from the knee must exceed pain experienced from any other condition.~* Patients must be willing and able to discontinue all current analgesic treatment.~Exclusion Criteria:~* Any other form of arthritis than osteoarthritis.~* Presence of neuropathic pain, or fibromyalgia, or wide spread chronic pain not related to osteoarthritis.~* Significant abnormalities on the clinical examination that may interfere with the study or present a safety risk to the patient, as judged by the investigator.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of 1 of the following:~  * Acute myeloid leukemia (AML), meeting any of the following criteria:~    * Relapsed disease~   * AML arising from myelodysplastic syndromes~   * Primary refractory disease~   * De novo AML with high-risk features~ * Acute lymphoblastic leukemia (ALL), meeting any of the following criteria:~    * De novo ALL that is Philadelphia chromosome positive or with t(4,11) cytogenetic features~   * Relapsed disease~ * Multiple myeloma (in need of treatment)~* Planning to undergo HLA-matched related sibling nonmyeloablative hematopoietic stem cell transplantation~PATIENT CHARACTERISTICS:~* Not specified~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HCV RNA \>= 10\^3 IU/ml at screening~* Chronic HCV infection, defined as positive HCV antibody and/or HCV RNA more than 6 months prior to screening~* HCV Genotype 1, 2, 3, 4, 5 or 6~* Otherwise eligible for lung transplant at study site~Exclusion Criteria:~* Age \<18~* Treatment with any of the following agents:~  * Amiodarone. Subjects previously treated with amiodarone must have stopped the amiodarone at least 60 days prior to day 1 SOF/VEL~ * Carbamazepine, phenytoin, phenobarbital, oxcarbazepine~ * Rifabutin, rifampin or rifapentine~ * HIV regimens containing tenofovir or tipranavir/ritonavir~ * St John's wort~ * PPIs, including: Omeprazole, pantoprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole~ * Modafinil~* Have any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment or compliance~* Hepatitis B surface antigen positive~* History of hepatic encephalopathy or variceal hemorrhage~* Abnormal hematological and biochemical parameters, including:~  * Hemoglobin \<8g/dL~ * Platelets \<= 50,000/mm\^3~ * ALT (alanine aminotransferase), AST (aspartase aminotransferase) or alkaline phosphatase \>=10 times ULN~ * Total bilirubin \>3mg/dL~ * Severe renal impairment, ie creatinine clearance (CrCl) \<30mL/min~* Pregnant women or women planning to become pregnant~* Women or are breastfeeding~* Active or recent history (\<=1 year) of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epclusa (Type: OTHER): Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post-extubation Boussignac CPAP System in Adults With Moderate to Severe Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-\> 18 years of age~* ASA II-IV~* Previous diagnosis of moderate to severe obstructive sleep apnea~* diagnosed via polysomnography~* BMI \< 40~* scheduled for an abdominal or peripheral surgical procedure requiring endotracheal intubation and admission to hospital~Exclusion Criteria:~* BMI \> 40~* Age \<18 years~* inability to provide signed informed consent~* intra-thoracic~* head or neck surgery~* contraindication for immediate post-extubation application of CPAP~* not expected to be eligible for timely extubation following the surgical procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Boussignac CPAP device (Type: EXPERIMENTAL): Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
- standard CPAP (Type: ACTIVE_COMPARATOR): Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Infant Weight Gain With Trisomy 21 and CAVC

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants with Trisomy 21 and CAVC operated on at CHOA at Egleston between January 1, 2001 and December 31, 2005 will be included in the study.~Exclusion Criteria:~* Patients will be excluded if the following information is not available:~A. Birth weight B. Weight at operation C. Incomplete medical records e.g. patient followed preoperatively elsewhere

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Year
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male/female and 6 to 17 years of age at the time of study with hypertension (high blood pressure)~* Patient is able to swallow tablets~* Females of child bearing potential must use acceptable contraception throughout the trial~Exclusion Criteria:~* Patient has a history of heart, metabolic or kidney disease~* Patient has a history of known heart, lung, liver and other body system disorders~* Patient is pregnant or nursing~* Patient has participated in another clinical trial within the last 28 days

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Losartan 50 mg (Type: ACTIVE_COMPARATOR): Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
- Losartan 100 mg (Type: ACTIVE_COMPARATOR): Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
- Losartan 50 mg/HCTZ 12.5 mg (Type: EXPERIMENTAL): Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
- Losartan 100 mg/HCTZ 12.5 mg (Type: EXPERIMENTAL): Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed squamous cell carcinoma of the head and neck~  * Locally advanced or metastatic disease~    * No patients with locally advanced disease for whom radiotherapy is indicated~ * Recurrent disease~ * Incurable disease~* Measurable disease by RECIST criteria~  * Recurrent disease within a prior radiation field can be considered to be measurable~* Patients may have received 1 line of prior chemotherapy (but not a taxane) for locally advanced or metastatic disease~* Patients may have received prior radiation therapy for locally advanced or metastatic disease (but must have completed the radiotherapy \> 6 months before recruitment)~  * No disease relapsed within 6 months of radiotherapy~* No evidence of central nervous system metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 12 weeks~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Hemoglobin ≥ 10 g/dL~* Urea and creatinine normal~* Serum bilirubin normal~* AST or ALT ≤ 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase \< 2.5 times ULN~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 3 months (female) or 2 months (male) after the last dose of the study treatment~* No uncontrolled infection~* No mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study~* No prior malignancy likely to interfere with the patient's ability to comply with treatment and/or follow up~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy for any cancer, except for head and neck cancer~* No prior taxane~* No prior therapy with any erbB inhibitors (except cetuximab given with radiotherapy, as indicated in treatment algorithm)~* More than 6 months since prior radiotherapy for locally advanced or metastatic disease~* At least 4 weeks since prior investigational drug~* No concurrent use of drugs known to inhibit CYP3A4 (except dexamethasone), or block P-glycoprotein, including grapefruit juice~* No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, or experimental medications~* No concurrent live vaccines during everolimus therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient meets ROME III criteria for functional dyspepsia (FD)~* Patient has a normal esophagogastroduodenoscopy (EGD) either during the Screening Period or within 2 years of the Screening Visit~* Patients who EITHER:~  1. Have not used a proton pump inhibitor (PPI) within 4 weeks of the Screening Visit, OR~ 2. Have used a PPI at a stable dose for at least 4 weeks prior to the Screening Visit;~* Patient meets symptom severity criteria in the Pretreatment Period~* Patient is fluent and literate in Dutch, French, or English~Exclusion Criteria:~* Patient meets criteria for gastroesophageal reflux disease (GERD, stable regimen of PPIs acceptable), constipation, diarrhea, lower abdominal pain, or gastroparesis~* Patient has a history of inflammatory bowel disease, chronic pancreatitis, small intestinal bacterial overgrowth, celiac disease, lactose intolerance, polycystic kidney disease, interstitial cystitis, or scleroderma~* Any significant neurological disease or a history of cancer (resected basal cell or squamous cell carcinoma of the skin is acceptable; complete remission of other cancers for 5 years or longer is also acceptable)~* History of active alcoholism or drug addiction within 12 months prior to the Screening Visit~* Hospitalized for a psychiatric condition or has made a suicide attempt during the two years before the Screening Visit~* Any organic or structural disease that can cause abdominal pain or discomfort

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IW-9179 (Type: EXPERIMENTAL): Oral IW-9179 taken daily for two weeks
- Placebo (Type: PLACEBO_COMPARATOR): Oral placebo taken daily for two weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glyburide vs Glucovance in the Treatment of GDM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational diabetes~* Pregnancy \> 12 weeks gestation~* Ability to give consent~Exclusion Criteria:~* Inability to consent to the study~* Pre-existing diabetes~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Serum creatinine \>1~* Liver disease~* Allergy to sulfa;~* Allergy to glyburide;~* Allergy to metformin;~* Fetal anomalies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glyburide (Type: ACTIVE_COMPARATOR): * Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~* The dose of glyburide will be increased as needed to a maximum of 20mg /day.~* Antenatal testing will be initiated at 28 weeks~* Patients will receive monthly growth scans
- Glucovance (Type: ACTIVE_COMPARATOR): * Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~* The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~* Patients will receive monthly growth scans~* Antenatal testing will be initiated at 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. AD patients with moderate to severe AD who are indicated for treatment with dupilumab~2. Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy allergic subjects, with a well-documented medical history of reactions after ingestion.Peanut, hazelnut, walnut, cow's milk, hen's egg and/or soybean allergy specific immunoglobulin E (IgE) level (Phadia CAP-system) higher than 0.35 kU/L or a skin prick test of at least 3 mm~3. Positive double-blind placebo-controlled Food Challenge (DBPCFC) with an eliciting dose before the last dose~4. Signed Bioday informed consent from subjects~Exclusion Criteria:~1. Subjects reacting objectively to the placebo at screening.~2. Subjects in whom DBCPFC is contra-indicated or in whom DBPCFC is not reliable

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Treatment for Night-Eating Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 - 65 years of age~2. English speaking~3. Meet DSM-V (Diagnostic and Statistical Manual - version 5) criteria for Night Eating Syndrome (NES)~Exclusion Criteria:~1. Unable to provide informed consent~2. Presence of alcohol/substance dependence~3. Presence of other eating disorders such as Binge Eating Disorder, Anorexia Nervosa.~4. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease)~5. Women who are pregnant or breastfeeding~6. Allergy or hypersensitivity to melatonin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Melatonin (Type: EXPERIMENTAL): A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo capsules to be administered once a day for a total of 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Ultrasound (EUS) Guided Ethanol With Paclitaxel Ablation for Pancreatic Mucinous Cystic Neoplasm

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Mucinous cystic neoplasm defined by cyst fluid analysis \[23, 28\]:~   * CEA \> 192ng/mL~  * Amylase \< 800 IU/L~  * Cytology negative for malignant cells~  * No communication of cyst with pancreatic duct on 2 imaging studies (EUS, CT, MRCP, or ERCP)~2. Cyst size \> 15mm but \<50mm~3. 3 or fewer cyst compartments~4. Age ≥18 and ≤ 85~Exclusion Criteria:~1. Inability to safely undergo EUS examination with standard conscious sedation~2. Inability for safe FNA needle insertion into the cyst (eg: intervening vessel)~3. Inability to undergo MRI (metal implants/cardiac pacemaker/defibrillator, claustrophobia)~4. Coagulopathy (INR\>1.5 or platelets\<50)~5. Active pancreatitis or pancreatic infection~6. Active sepsis/bacteremia~7. Inability to provide informed consent~8. Pregnancy~9. Breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ethanol and Paclitaxel Injection (Type: EXPERIMENTAL): All patients will receive at least one treatment with alcohol and paclitaxel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Two Treatment Regimens of Cocamide DEA Lotion for Head Lice

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients over the age of 4 who are found to have a head louse infection.~* Patients who give written informed consent and, if the patient is under 16 years of age, whose guardian gives written informed consent to participate in the study.~* Available for the duration of study i.e. 15 days.~Exclusion Criteria:~* Patients with a known sensitivity to paraben preservatives.~* Patients who have been treated with other head lice products within the last 2 weeks.~* Patients who have undergone a course of antibiotic treatment within the last 4 weeks.~* Patients who have any persistent skin disorder of the scalp (i.e. eczema, chronic dermatitis, psoriasis).~* Patients whose hair has been bleached, colour treated or permed within the last 4 weeks.~* Patients who have participated in another clinical trial within 1 month prior to entry to this study.~* Patients who have already participated in this clinical trial.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 10% Cocamide diethanolamine 8 hours (Type: EXPERIMENTAL): Cocamide DEA topical lotion applied 8 hours/overnight with drying
- 10% Cocamide diethanolamine 2 hours (Type: EXPERIMENTAL): Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy